STOCK ALARMSA

Demo Log In

Canopy Growth Corporation(CGC)

$1.03—

Chart

Canopy Growth Corporation(CGC)

NASDAQ

$1.03—

Chart Studio

CGC(CGC)

CGC

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Writing up the research note…

First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

8/27/26

CANOPY GROWTH (CGC)

Thursday

6:32 AM

Thesis: Canopy Growth: the story is balanced — US federal cannabis legalization or rescheduling developments - potential market access to $30B+ US market drives…

Revenue Outlook

Metric	FY2026	FY2027E	FY2028E
Revenue	$285M	$250M	$270M
Rev. Growth	+5.8%	-12.2%	+8.1%
EPS	$-0.88	$-0.10	$-0.08
EPS Growth	+84.1%	+88.2%	+23.3%
P/E	—	—	—

★ Analysts see FY2028 revenue reaching $270M — +8.1% growth in a single year.

What Moves the Stock

1US federal cannabis legalization or rescheduling developments - potential market access to $30B+ US market drives speculative positioning
2Canadian market pricing trends - wholesale cannabis prices per gram directly impact gross margins and path to profitability
3Cash burn rate and liquidity runway - company has burned through $2B+ since 2020, requiring equity raises or asset sales
4Quarterly revenue trajectory and market share in Canadian recreational segment - indicates competitive positioning versus Aurora, Tilray, Hexo
5Strategic partnerships or M&A activity - consolidation potential in fragmented cannabis sector
6Canadian recreational cannabis (estimated 65-70% of revenue) - dried flower, pre-rolls, vapes, edibles sold through provincial distributors
7Canadian medical cannabis (estimated 15-20%) - direct-to-patient sales through Spectrum Therapeutics platform
8International medical cannabis (estimated 10-15%) - exports to Germany, Australia, and other markets with medical programs

FY2026 Snapshot

Revenue: $285M
Rev. Growth: +5.8%
Gross Margin: 24.5%
Op. Margin: -25.7%
Net Margin: -92.4%
Net Income: $-263M
NI Growth: +56.0%
EPS: $-0.88
1Y Return: -28.1%

CGC Chart

My Notes

momentum/speculative - The stock attracts retail traders and speculative investors betting on US federal legalization catalysts or sector…
High sensitivity through multiple channels.
Watch on earnings: US congressional activity on cannabis rescheduling (DEA Schedule III classification) or SAFE Banking Act passage, Canadian wholesale cannabis price per gram - Statistics Canada monthly data on average transaction prices, Quarterly cash burn rate and adjusted EBITDA trajectory toward breakeven.

One Sentence Summary:

Canopy Growth: the story is balanced — us federal cannabis legalization or rescheduling developments - potential market access to $30b+ us market drives speculative positioning.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.